Insider Selling: Craig A. Wheeler Sells 2,110 Shares of Momenta Pharmaceuticals Stock (MNTA)
Momenta Pharmaceuticals (NASDAQ:MNTA) President Craig A. Wheeler unloaded 2,110 shares of the company’s stock on the open market in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $12.06, for a total value of $25,446.60. Following the sale, the president now directly owns 374,054 shares in the company, valued at approximately $4,511,091. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) opened at 12.73 on Wednesday. Momenta Pharmaceuticals has a one year low of $9.85 and a one year high of $19.90. The stock’s 50-day moving average is $11.29 and its 200-day moving average is $15.44. The company’s market cap is $655.0 million.
Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its earnings results on Tuesday, May 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.02. The company had revenue of $10.79 million for the quarter, compared to the consensus estimate of $8.41 million. During the same quarter in the previous year, the company posted ($0.48) earnings per share. The company’s revenue for the quarter was up 42.1% on a year-over-year basis. On average, analysts predict that Momenta Pharmaceuticals will post $-0.43 earnings per share for the current fiscal year.
A number of research firms have recently commented on MNTA. Analysts at Maxim Group initiated coverage on shares of Momenta Pharmaceuticals in a research note on Friday, May 9th. They set a “buy” rating and a $24.00 price target on the stock. Separately, analysts at Bank of America upgraded shares of Momenta Pharmaceuticals from an “underperform” rating to a “buy” rating in a research note on Wednesday, May 7th. Finally, analysts at Canaccord Genuity reiterated a “buy” rating on shares of Momenta Pharmaceuticals in a research note on Wednesday, May 7th. They now have a $17.00 price target on the stock, down previously from $22.00. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $20.20.
Momenta Pharmaceuticals, Inc (NASDAQ:MNTA) is a biotechnology company specializing in the characterization and process engineering of complex molecules.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.